Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2019 3
2020 6
2021 4
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Tertiary lymphoid structures as local perpetuators of organ-specific immune injury: implication for lupus nephritis.
Wang M, Rajkumar S, Lai Y, Liu X, He J, Ishikawa T, Nallapothula D, Singh RR. Wang M, et al. Front Immunol. 2023 Oct 31;14:1204777. doi: 10.3389/fimmu.2023.1204777. eCollection 2023. Front Immunol. 2023. PMID: 38022566 Free PMC article. Review.
Resolution of TLS, along with improvement in lupus, by treating animals with soluble BAFF receptor, docosahexaenoic acid, complement inhibitor C4BP(beta-), S1P1 receptor modulator Cenerimod, dexamethasone, and anti-CXCL13 further emphasizes a role of TLS in the pathogenesi …
Resolution of TLS, along with improvement in lupus, by treating animals with soluble BAFF receptor, docosahexaenoic acid, complement inhibit …
Lack of Effect of Cenerimod, a Selective S1P(1) Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive.
Juif PE, Mueller MS, Charfi H, Dingemanse J. Juif PE, et al. Int J Mol Sci. 2022 Nov 29;23(23):14986. doi: 10.3390/ijms232314986. Int J Mol Sci. 2022. PMID: 36499313 Free PMC article. Clinical Trial.
Overall, COC alone or in combination with cenerimod was safe and well tolerated. Two subjects reported one adverse event each (one headache after COC alone, and gastroenteritis in combination with cenerimod 4 mg). In conclusion, cenerimod does not affect the …
Overall, COC alone or in combination with cenerimod was safe and well tolerated. Two subjects reported one adverse event each (one he …
In Vitro Characterization of Sphingosine 1-Phosphate Receptor 1 (S1P(1)) Expression and Mediated Migration of Primary Human T and B Cells in the Context of Cenerimod, a Novel, Selective S1P(1) Receptor Modulator.
Schlicher L, Kulig P, von Münchow A, Murphy MJ, Keller MP. Schlicher L, et al. Int J Mol Sci. 2022 Jan 21;23(3):1191. doi: 10.3390/ijms23031191. Int J Mol Sci. 2022. PMID: 35163112 Free PMC article.
Cenerimod is a potent, selective sphingosine 1-phosphate receptor 1 (S1P(1)) modulator currently investigated in a Phase IIb study in patients with systemic lupus erythematosus (SLE) (NCT03742037). ...Here, we show that cenerimod effectively prevents T and B cell mi …
Cenerimod is a potent, selective sphingosine 1-phosphate receptor 1 (S1P(1)) modulator currently investigated in a Phase IIb study in …
Cenerimod, a selective S1P(1) receptor modulator, improves organ-specific disease outcomes in animal models of Sjogren's syndrome.
Gerossier E, Nayar S, Froidevaux S, Smith CG, Runser C, Iannizzotto V, Vezzali E, Pierlot G, Mentzel U, Murphy MJ, Martinic MM, Barone F. Gerossier E, et al. Arthritis Res Ther. 2021 Nov 29;23(1):289. doi: 10.1186/s13075-021-02673-x. Arthritis Res Ther. 2021. PMID: 34839819 Free PMC article.
Based on the mechanism of action of cenerimod, its efficacy was evaluated in two mouse models of Sjogren's syndrome. ...The effects of cenerimod treatment were then evaluated by flow cytometry, immunohistochemistry, histopathology and immunoassays. ...
Based on the mechanism of action of cenerimod, its efficacy was evaluated in two mouse models of Sjogren's syndrome. ...The effects o …
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Pérez-Jeldres T, et al. Drugs. 2021 Jun;81(9):985-1002. doi: 10.1007/s40265-021-01528-8. Epub 2021 May 13. Drugs. 2021. PMID: 33983615 Free PMC article. Review.
Ozanimod and etrasimod have shown promising results in IBD; while in phase 2 clinical trials, ponesimod has shown improvement in 77% of the patients with psoriasis. Cenerimod and amiselimod have been tested in SLE patients. Fingolimod, etrasimod, and IMMH001 have shown eff …
Ozanimod and etrasimod have shown promising results in IBD; while in phase 2 clinical trials, ponesimod has shown improvement in 77% of the …
Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus.
Strasser DS, Froidevaux S, Sippel V, Gerossier E, Grieder U, Pierlot GM, Kieninger-Graefitsch A, Vezzali E, Stalder AK, Renault B, Ryge J, Hart A, Mentzel U, Groenen PMA, Keller MP, Trendelenburg M, Martinic MM, Murphy MJ. Strasser DS, et al. RMD Open. 2020 Sep;6(2):e001261. doi: 10.1136/rmdopen-2020-001261. RMD Open. 2020. PMID: 32917831 Free PMC article.
METHODS: Cenerimod effect on lymphocyte numbers, organ pathology, inflammation, and survival was evaluated in the MRL/lpr lupus mouse model. ...CONCLUSION: Cenerimod significantly ameliorated systemic and organ-specific pathology and inflammation in a mouse model of …
METHODS: Cenerimod effect on lymphocyte numbers, organ pathology, inflammation, and survival was evaluated in the MRL/lpr lupus mouse …
Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P(1) R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects.
Juif PE, Dingemanse J, Winkle P, Ufer M. Juif PE, et al. Clin Transl Sci. 2021 Jan;14(1):143-147. doi: 10.1111/cts.12873. Epub 2020 Sep 10. Clin Transl Sci. 2021. PMID: 32860737 Free PMC article. Clinical Trial.
Cenerimod is a sphingosine-1-phosphate 1 receptor (S1P(1) R) modulator in phase II development for treatment of systemic lupus erythematosus. ...In conclusion, the determined absence of any relevant PK or PD differences supports using the same doses of cenerimod in …
Cenerimod is a sphingosine-1-phosphate 1 receptor (S1P(1) R) modulator in phase II development for treatment of systemic lupus erythe …
Estimation of Attainment of Steady-State Conditions for Compounds With a Long Half-Life.
Krause A, Lott D, Dingemanse J. Krause A, et al. J Clin Pharmacol. 2021 Jan;61(1):82-89. doi: 10.1002/jcph.1701. Epub 2020 Jul 12. J Clin Pharmacol. 2021. PMID: 32656870 Review.
The relevance of accurate estimation of time to attainment of steady state is illustrated with cenerimod, an sphingosine-1-phosphate 1 receptor modulator with long half-life currently in clinical development for which estimates of time to steady state ranged from 35 to 110 …
The relevance of accurate estimation of time to attainment of steady state is illustrated with cenerimod, an sphingosine-1-phosphate …
Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P(1) receptor modulator in healthy subjects.
Boof ML, van Lier JJ, English S, Fischer H, Ufer M, Dingemanse J. Boof ML, et al. Xenobiotica. 2020 Aug;50(8):947-956. doi: 10.1080/00498254.2020.1736688. Epub 2020 Mar 9. Xenobiotica. 2020. PMID: 32105166
Cenerimod is a sphingosine-1-phosphate 1 receptor modulator under development for treatment of systemic lupus erythematosus.This single-centre, open-label, single-dose study investigated the mass balance and excretion routes and aimed at identifying and quantifying cene …
Cenerimod is a sphingosine-1-phosphate 1 receptor modulator under development for treatment of systemic lupus erythematosus.This sing …
16 results